Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 1997

View Archived Issues

Clinical results in NIDDM reported for troglitazone

Pioglitazone improves insulin resistance in NIDDM

New preclinical studies on JTT-501

Phase III results for AY-4166

Clinical safety and efficacy of TS-110 for inflammation and pain

Carbovir not associated with mitochondrial toxicity in intact cells

BRL-48482 has potential for reducing cardiovascular risk in NIDDM

Paracelsian cancels launch of AndroVir

Novel site of action for chimeric insulin-releasing peptide

Otsuka AGE inhibitor prevents progression of diabetic nephropathy in animal model

Novopharm Biotech files Canadian IND for hMAb

Promising preliminary results with Oncor's HER-2/neu in prostate trial

M-16049: hypoglycemic agent and aldose reductase inhibitor

Mylan files ANDA for generic nifedipine

MedImmune: Q1 1997 highlights

Cambridge Antibody Technology: Six-month results and highlights

Ergoset clinical study results presented at diabetes congress

A wealth of clinical data on pramlintide presented at diabetes congress

FDA clears Hemagen Diagnostics' test for connective tissue diseases

Arris and Abbott sign licensing agreement

Harvard Medical School and Hoechst Marion Roussel enter research agreement

Alfa Wassermann and Merckle sign development and marketing agreement for rifaximin

Paracelsian cancels launch of AndroCar

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...